Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies

AIDS

Volumn 17, Issue 18, 2003, Pages 2629-2634

  Wood, Evan ^a,b   Hogg, Robert S ^a,b   Heath, Katherine V ^a,b   De La Rosa, Rafael ^c   Lee, Nelson ^a   Yip, Benita ^a   Q'Shaughnessy, Michael V ^a,b   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Non nucleoside reverse transcriptase inhibitors; Observational cohort; Protease inhibitors; Provider bias

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATION; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DELAVIRDINE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXAZINES; PREJUDICE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 1642505799     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200312050-00010     Document Type: Article

References (21)

1. US Public Health Service. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Updated 4 February 2002. Available at: http://www.aidsinfo.nih.gov. Accessed 20 August 2003.
2. British HIV Association (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001, 2:276-313.
3. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.
4. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (ICoNA) study. J Infect Dis 2002, 185:1062-1069.
5. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002, 3:296-303.
6. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001, 15:1133-1142.
7. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001, 27:350-364.
8. Grabar S, Arvieux C, Lang JM, Pradier C, Reliquet V, Simon A, et al. Virologic and clinical outcomes in pretreated patients receiving regimen containing a protease inhibitor or a non nucleoside analogue as first HAART. In: XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract B10200].
9. De Wolf F, Van de Wiel MA, Van Sighem AI, Ghani AC. Effectiveness of long-term HAART regimens in treatment naive and experienced patients in a large observational cohort (ATHENA). In: XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract THPeC7440].
10. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, et al. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined together with stavudine and lamivudine. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 10-14 February 2003 [Abstract 176].
11. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999, 13:2075-2082.
12. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
13. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003, 17:711-720.
14. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560-2567.
16. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000, 23:360-361.
17. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972, 34:187-202.
18. Hogg RS, Heath KV, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002, 16:1051-1058.
19. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
20. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000, 14:1955-1960.
21. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. The AVANTI and INCAS Study Groups [In Process Citation]. AIDS 2000, 14:1383-1388.